Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Anticoagulation Is Important Element of Adjunctive Therapy in Thrombosis Management

April 16th 2020

Alvin H. Schmaier, MD, discusses the primary and secondary management of cancer-related thrombosis.

Genomic Profiling Shows Clinical Utility in Select Sarcomas

April 15th 2020

Comprehensive genomic profiling can be successfully performed in the majority of patients with sarcoma, depending on the tumor location and tissue subtype, which can impact treatment decisions and patient outcomes.

Innovative plasmaMATCH Trial Displays Feasibility With ctDNA in Breast Cancer

April 15th 2020

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

High BMI, Weight Gain Tied to Increased Mortality in Prostate Cancer

April 13th 2020

Obese men with nonmetastatic prostate cancer have higher cardiovascular disease–related mortality and all-cause mortality, and potentially increased prostate cancer–specific mortality.

Ongoing Research Efforts in Metastatic Ocular Melanoma Could Shift Paradigm

April 11th 2020

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.

Acalabrutinib Triplet Impresses in Frontline CLL, Advances to Phase III Study

April 7th 2020

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

MDS Armamentarium Expands With Luspatercept Approval, Novel Compounds

April 7th 2020

David P. Steensma, MD, discusses some new data in myelodysplastic syndromes and ongoing research in the space.

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC

April 3rd 2020

A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.

ctDNA Provides Prognostic and Predictive Value in Early-Stage Breast Cancer

April 3rd 2020

Circulating tumor DNA can be used as a predictive measure of response to neoadjuvant chemotherapy and inform overall prognosis in patients with early-stage breast cancer, providing information that can be used to tailor treatment.

Marshall Reflects on Major Advances in mCRC

April 1st 2020

John L. Marshall, MD, reflects on recent advances in the field of metastatic colorectal cancer and discusses ongoing research efforts in the space.

Novel Hormonal Agents Foster New Approaches in Nonmetastatic CRPC

April 1st 2020

Nonmetastatic castration-resistant prostate cancer is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available.

Charting New Territory in Multiple Myeloma Amid COVID-19 Crisis

March 31st 2020

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

PD-1 Inhibition Reigns Supreme in Frontline Advanced RCC

March 31st 2020

The role of immunotherapy in metastatic renal cell carcinoma has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors.

PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer

March 31st 2020

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.

Engineering Immune Response With In-Situ Vaccines in iNHL

March 26th 2020

Joshua Brody, MD, discusses research with in-situ vaccination in non-Hodgkin lymphoma and strategies being developed to overcome acquired resistance.

More Data Needed to Guide Cancer Care Decisions Amid COVID-19 Crisis

March 26th 2020

Petros Grivas, MD, discusses the repercussions of the COVID-19 pandemic on oncology practice patterns and the importance of contributing to the COVID-19 and Cancer Consortium Registry.

UCSF Takes Steps to Stop COVID-19 Spread, Ensure Patient Safety

March 24th 2020

Thomas G. Martin, MD, discusses the risk of COVID-19 to patients with cancer and precautionary measures implemented by the the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.

SCLC Paradigm Advances With Immunotherapy, Integration of Rapid Research Autopsies

March 23rd 2020

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.

Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC

March 23rd 2020

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.